Breaking News, Collaborations & Alliances

Exelixis, BMS Enter Multiple Drug Pacts

Exelixis, Inc. and Bristol-Myers Squibb have entered a collaboration agreement under which Exelixis will grant BMS an exclusive license to its small-molecule TGR5 agonist program, including backups.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Exelixis, Inc. and Bristol-Myers Squibb have entered a collaboration agreement under which Exelixis will grant BMS an exclusive license to its small-molecule TGR5 agonist program, including backups. The two companies will also collaborate to discover, optimize, and characterize small-molecule ROR antagonists. In addition, Exelixis and BMS have made minor amendments to their XL281 and liver X receptor (LXR) agreements, and Exelixis has opted out of further co-development of XL139 and will receive...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters